As India grapples with a deadly surge among its population of 1.4 billion, worries are growing for many other spots all over the planet.
For James Paton's latest contributions to The Japan Times, see below:
Some experts are worried about the potential impact of widely deploying Chinese shots that have demonstrated lower efficacy rates than those made by Pfizer and Moderna.
Reviews by U.K. and European Union regulators finding potential links to the unusual side effects are another blow for the shot.
The COVID-19 Genomics U.K. Consortium has become a global model for analyzing genomes for signs that the coronavirus is gaining power to spread — or to kill.
Dangerous coronavirus variants are carpeting the globe, pushing scientists in the U.K. and elsewhere to target multiple versions of the pathogen in a single shot.
Global gaps in access to vaccines are raising concerns that the spread of the virus will breed more dangerous versions of the pathogen, weakening medical weapons.
Even with the latest technologies, money and might behind the unprecedented global drive to knock out COVID-19, the disease is unlikely to be eliminated any time soon.
The encouraging late-stage trial results from Pfizer Inc. and Moderna Inc. set a high bar for rivals that are expected to follow soon with their own pivotal reports.
Fading trust in governments, political interference and the dash to create a shot in record time are sowing doubts.
After COVID-19’s emergence in Buenos Aires led to a strict lockdown in March, Juliana Cassataro and her fellow vaccine researchers grew concerned. The U.S., Europe and China had already revved up their quests to obtain shots; how far back in line would Argentina have ...